ProKidney Set for Upcoming Healthcare Conferences
WINSTON-SALEM, N.C. — ProKidney Corp. (Nasdaq: PROK), a leader in the clinical-stage cellular therapeutics field, is excited to announce that its senior management will be participating in two significant healthcare conferences this September. These conferences are an excellent opportunity for ProKidney to showcase its advancements and innovations in treating chronic kidney disease (CKD).
Citi Biopharma Back to School Conference
One of the first events on the agenda is the Citi Biopharma Back to School Conference. This event is scheduled for September 3 and will be hosted in Boston. The format will be a fireside chat, offering an intimate setting where discussions can easily flow. ProKidney’s engagement in this conference demonstrates its commitment to sharing insights and developments with key stakeholders in the healthcare community.
Event Details
The Citi Biopharma Conference will begin at 10:30 AM ET. Attendees can follow the discussion and gain valuable insights into the company's research and future plans. The session can be accessed through the Investor Relations section of ProKidney's website.
Morgan Stanley Global Healthcare Conference
Following the Citi event, ProKidney will participate in the Morgan Stanley Global Healthcare Conference, happening on September 8 in New York. This major conference is known for gathering prominent healthcare voices, and ProKidney is honored to be part of it.
What to Expect
Another fireside chat format will facilitate open discussions at 7:00 AM ET. ProKidney's executives will share key updates about the company's ongoing Phase 3 REGEN-006 study, highlighting the potential benefits of their leading product candidate, rilparencel. Attendees can expect in-depth conversation about ProKidney's innovations and how they aim to significantly improve the treatment landscape for CKD patients.
Access to Live Webcasts
For those interested in following the live coverage, both sessions will be available via webcast on ProKidney's website. This provides a perfect avenue for investors and interested parties to stay informed about the latest developments in the field of chronic kidney disease.
About ProKidney Corp.
ProKidney has positioned itself as a pioneer in treating chronic kidney disease through advanced cellular therapy innovations. Established in 2015, ProKidney's dedication stems from over a decade of extensive research. Its primary product, rilparencel, is celebrated for being the first of its kind and comes with proprietary and patented technology. This cellular therapy is currently undergoing evaluation in the ongoing Phase 3 trial, showing promise in preserving kidney function for advanced CKD patients, especially those alongside type 2 diabetes.
Further Information
Investors or professionals looking for more details about ProKidney executive insights or potential collaborations are encouraged to reach out through the official channels provided on the website.
Frequently Asked Questions
What is ProKidney Corp. known for?
ProKidney Corp. focuses on developing innovative therapies for chronic kidney disease, particularly through cellular therapeutic advancements.
When will ProKidney participate in the upcoming conferences?
ProKidney will participate in the Citi Biopharma Back to School Conference on September 3 and the Morgan Stanley Global Healthcare Conference on September 8.
What is rilparencel?
Rilparencel is ProKidney’s leading product candidate, recognized as a first-in-class cellular therapy aimed at preserving kidney function in patients with advanced CKD.
How can investors learn more about ProKidney?
Investors can visit ProKidney's website, specifically the Investor Relations section, for updates and access to webcasts of upcoming conference sessions.
Who can be contacted for investor relations?
For investor inquiries, Ethan Holdaway from ProKidney and Daniel Ferry from LifeSci Advisors are available for contact through their respective emails provided in the announcements.